Matches in SemOpenAlex for { <https://semopenalex.org/work/W2905241205> ?p ?o ?g. }
- W2905241205 endingPage "895" @default.
- W2905241205 startingPage "895" @default.
- W2905241205 abstract "Abstract BACKGROUND Tisagenlecleucel is an FDA approved chimeric antigen receptor (CAR)-T cell therapy that reprograms T cells to eliminate CD19+ B cells. ELIANA (NCT02435849) is a phase 2 pivotal study of tisagenlecleucel in pediatric/young adult patients (pts) with CD19+ r/r B-cell acute lymphoblastic leukemia (ALL), the first global trial of a CAR-T cell therapy. The primary objective was met, with an overall remission rate (ORR) of 81% (complete remission [CR] + CR with incomplete blood count recovery [CRi]). Here we present an update of ELIANA, with additional pts and additional 11 mo follow-up from the previous report (Maude et al. N Engl J Med 2018). METHODS Eligible pts were aged ≥3 y at screening and ≤21 y at diagnosis and had ≥5% leukemic blasts in bone marrow. Tisagenlecleucel was centrally manufactured at 2 sites (Morris Plains, NJ, USA and Leipzig, Germany) by lentiviral transduction of autologous T cells with a vector encoding for a second generation 4-1BB anti-CD19 CAR and expanded ex vivo. Tisagenlecleucel was provided to pts at 25 study centers in 11 countries on 4 continents using cryopreserved apheresed mononuclear cells, central production facilities, and a global supply chain. The primary endpoint, ORR within 3 mo and maintained for ≥28 d among infused pts, was assessed by an independent review committee. Secondary endpoints included duration of remission (DOR), overall survival (OS), safety, and cellular kinetics. RESULTS As of April 13, 2018, 113 pts were screened and 97 enrolled. There were 8 manufacturing failures (8%) and 10 pts (10%) were not infused due to death or adverse events (AEs). Following lymphodepleting chemotherapy in most pts (76/79; fludarabine/cyclophosphamide [n=75]), 79 pts were infused with a single dose of tisagenlecleucel (median dose, 3.0×106 [range, 0.2-5.4×106] CAR-positive viable T cells/kg), and all had ≥3 mo of follow-up or discontinued earlier (median time from infusion to data cutoff, 24 mo [range, 4.5-35 mo]). Median age was 11 y (range, 3-24 y); 61% of pts had prior hematopoietic stem cell transplant (SCT). Among the 65 pts with CR/CRi, 64 (98%) were MRD- within 3 mo. Median DOR by K-M analysis was not reached (Figure): responses were ongoing in 29 pts (max DOR, 29 mo and ongoing); 19 pts relapsed before receiving additional anticancer therapy (13 died subsequently); 8 pts underwent SCT while in remission, 8 received additional anticancer therapy (non-SCT) and 1 discontinued while in remission. The probability of relapse-free survival at 18 mo was 66% (95% CI, 52%-77%). Median OS was not reached; OS probability at 18 mo was 70% (95% CI, 58%-79%). Cytokine release syndrome (CRS) occurred in 77% of pts (grade [G] 3/4; 48%; graded using the Penn scale); 39% of pts received tocilizumab for treatment of CRS with or without other anti-cytokine therapies; 48% of pts required ICU-level care for CRS, with a median ICU stay of 7 d. All cases of CRS were reversible. Most common G 3/4 nonhematologic AEs (>15%) other than CRS were neutropenia with a body temperature >38.3°C (62% within 8 wk of infusion), hypoxia (20%), and hypotension (20%). 13% of pts experienced G 3 neurological events, with no G 4 events or cerebral edema. Based on laboratory results, 43% and 54% of pts had G 3/4 thrombocytopenia and neutropenia not resolved by d 28; the majority of events resolved to G ≤2 by 3 mo. 25 post-infusion deaths were reported: 2 within 30 d (1 disease progression, 1 cerebral hemorrhage); 23 after 30 d of infusion (range, 53-859 d; 18 disease progression, 1 each due to encephalitis, systemic mycosis, VOD [hepatobiliary disorders related to allogeneic-SCT], bacterial lung infection, and an unknown reason after study withdrawal). Tisagenlecleucel expansion in vivo correlated with CRS severity, and persistence of tisagenlecleucel along with B-cell aplasia in peripheral blood was observed for ≥2.5 y in some responding pts. Analysis of B-cell recovery and correlation with relapse will be presented. CONCLUSIONS With longer follow-up, the ELIANA study continues to confirm the efficacy of a single infusion of tisagenlecleucel in pediatric and young adults with ALL without additional therapy. AEs were effectively and reproducibly managed globally by appropriately trained personnel at study sites. The achievement of high overall response rates and deep remissions, in combination with the median duration of response and overall survival not being reached, further corroborate previously reported results. Figure. Figure. Disclosures Grupp: Novartis Pharmaceuticals Corporation: Consultancy, Research Funding; Jazz Pharmaceuticals: Consultancy; Adaptimmune: Consultancy; University of Pennsylvania: Patents & Royalties. Maude:Novartis Pharmaceuticals Corporation: Consultancy, Membership on an entity's Board of Directors or advisory committees. Rives:Shire: Consultancy, Other: Symposia, advisory boards ; Jazz Pharma: Consultancy, Other: Symposia, advisory boards ; Novartis Pharmaceuticals Corporation: Consultancy, Other: Symposia, advisory boards ; Amgen: Consultancy, Other: advisory board . Baruchel:Celgene: Consultancy; Amgen: Consultancy; Roche: Consultancy; Jazz Pharmaceuticals: Consultancy, Honoraria, Other: Travel, accommodations or expenses; Novartis: Membership on an entity's Board of Directors or advisory committees; Shire: Research Funding; Servier: Consultancy. Bittencourt:Novartis Pharmaceuticals Corporation: Consultancy; Jazz Pharmaceuticals: Consultancy, Honoraria. Bader:Riemser: Research Funding; Cellgene: Consultancy; Medac: Patents & Royalties, Research Funding; Neovii: Research Funding; Novartis: Consultancy, Speakers Bureau. Laetsch:Bayer: Consultancy; Pfizer: Equity Ownership; Eli Lilly: Consultancy; Novartis Pharmaceuticals Corporation: Consultancy; Loxo Oncology: Consultancy. Stefanski:Novartis Pharmaceuticals Corporation: Consultancy, Honoraria, Speakers Bureau. Myers:Novartis Pharmaceuticals Corporation: Consultancy, Honoraria, Research Funding, Speakers Bureau. Qayed:Novartis: Consultancy. Pulsipher:CSL Behring: Consultancy; Amgen: Honoraria; Adaptive Biotech: Consultancy, Research Funding; Novartis: Consultancy, Honoraria, Speakers Bureau. Martin:Novartis Pharmaceuticals Corporation: Research Funding; Jazz Pharmaceuticals: Research Funding. Nemecek:Novartis Pharmaceuticals Corporation: Other: advisory boards. Boissel:Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis Pharmaceuticals Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees. Leung:Novartis Pharmaceuticals Corporation: Employment. Eldjerou:Novartis Pharmaceuticals Corporation: Employment. Yi:Novartis Pharmaceuticals Corporation: Employment. Mueller:Novartis Institutes for Biomedical Research: Employment; Novartis Pharmaceuticals Corporation: Equity Ownership, Other: Patent pending. Bleickardt:Novartis Pharmaceuticals Corporation: Employment." @default.
- W2905241205 created "2018-12-22" @default.
- W2905241205 creator A5006173110 @default.
- W2905241205 creator A5009700060 @default.
- W2905241205 creator A5011992727 @default.
- W2905241205 creator A5012894919 @default.
- W2905241205 creator A5015116246 @default.
- W2905241205 creator A5015622625 @default.
- W2905241205 creator A5020712214 @default.
- W2905241205 creator A5024123180 @default.
- W2905241205 creator A5029816641 @default.
- W2905241205 creator A5034117075 @default.
- W2905241205 creator A5035520605 @default.
- W2905241205 creator A5042171388 @default.
- W2905241205 creator A5050787724 @default.
- W2905241205 creator A5052541853 @default.
- W2905241205 creator A5052844124 @default.
- W2905241205 creator A5055938005 @default.
- W2905241205 creator A5068149083 @default.
- W2905241205 creator A5068525415 @default.
- W2905241205 creator A5071401317 @default.
- W2905241205 creator A5071534196 @default.
- W2905241205 creator A5072425736 @default.
- W2905241205 creator A5076973611 @default.
- W2905241205 creator A5077440294 @default.
- W2905241205 creator A5078858949 @default.
- W2905241205 creator A5081348202 @default.
- W2905241205 creator A5084871192 @default.
- W2905241205 creator A5086872095 @default.
- W2905241205 creator A5087074127 @default.
- W2905241205 creator A5087551014 @default.
- W2905241205 date "2018-11-29" @default.
- W2905241205 modified "2023-10-12" @default.
- W2905241205 title "Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia" @default.
- W2905241205 doi "https://doi.org/10.1182/blood-2018-99-112599" @default.
- W2905241205 hasPublicationYear "2018" @default.
- W2905241205 type Work @default.
- W2905241205 sameAs 2905241205 @default.
- W2905241205 citedByCount "66" @default.
- W2905241205 countsByYear W29052412052018 @default.
- W2905241205 countsByYear W29052412052019 @default.
- W2905241205 countsByYear W29052412052020 @default.
- W2905241205 countsByYear W29052412052021 @default.
- W2905241205 countsByYear W29052412052022 @default.
- W2905241205 countsByYear W29052412052023 @default.
- W2905241205 crossrefType "journal-article" @default.
- W2905241205 hasAuthorship W2905241205A5006173110 @default.
- W2905241205 hasAuthorship W2905241205A5009700060 @default.
- W2905241205 hasAuthorship W2905241205A5011992727 @default.
- W2905241205 hasAuthorship W2905241205A5012894919 @default.
- W2905241205 hasAuthorship W2905241205A5015116246 @default.
- W2905241205 hasAuthorship W2905241205A5015622625 @default.
- W2905241205 hasAuthorship W2905241205A5020712214 @default.
- W2905241205 hasAuthorship W2905241205A5024123180 @default.
- W2905241205 hasAuthorship W2905241205A5029816641 @default.
- W2905241205 hasAuthorship W2905241205A5034117075 @default.
- W2905241205 hasAuthorship W2905241205A5035520605 @default.
- W2905241205 hasAuthorship W2905241205A5042171388 @default.
- W2905241205 hasAuthorship W2905241205A5050787724 @default.
- W2905241205 hasAuthorship W2905241205A5052541853 @default.
- W2905241205 hasAuthorship W2905241205A5052844124 @default.
- W2905241205 hasAuthorship W2905241205A5055938005 @default.
- W2905241205 hasAuthorship W2905241205A5068149083 @default.
- W2905241205 hasAuthorship W2905241205A5068525415 @default.
- W2905241205 hasAuthorship W2905241205A5071401317 @default.
- W2905241205 hasAuthorship W2905241205A5071534196 @default.
- W2905241205 hasAuthorship W2905241205A5072425736 @default.
- W2905241205 hasAuthorship W2905241205A5076973611 @default.
- W2905241205 hasAuthorship W2905241205A5077440294 @default.
- W2905241205 hasAuthorship W2905241205A5078858949 @default.
- W2905241205 hasAuthorship W2905241205A5081348202 @default.
- W2905241205 hasAuthorship W2905241205A5084871192 @default.
- W2905241205 hasAuthorship W2905241205A5086872095 @default.
- W2905241205 hasAuthorship W2905241205A5087074127 @default.
- W2905241205 hasAuthorship W2905241205A5087551014 @default.
- W2905241205 hasConcept C121608353 @default.
- W2905241205 hasConcept C126322002 @default.
- W2905241205 hasConcept C137061746 @default.
- W2905241205 hasConcept C143998085 @default.
- W2905241205 hasConcept C202751555 @default.
- W2905241205 hasConcept C203092338 @default.
- W2905241205 hasConcept C2777701055 @default.
- W2905241205 hasConcept C2778020697 @default.
- W2905241205 hasConcept C2778461978 @default.
- W2905241205 hasConcept C2780850621 @default.
- W2905241205 hasConcept C2909962599 @default.
- W2905241205 hasConcept C31760486 @default.
- W2905241205 hasConcept C3875195 @default.
- W2905241205 hasConcept C535046627 @default.
- W2905241205 hasConcept C55493867 @default.
- W2905241205 hasConcept C71924100 @default.
- W2905241205 hasConcept C86803240 @default.
- W2905241205 hasConcept C90924648 @default.
- W2905241205 hasConceptScore W2905241205C121608353 @default.
- W2905241205 hasConceptScore W2905241205C126322002 @default.
- W2905241205 hasConceptScore W2905241205C137061746 @default.
- W2905241205 hasConceptScore W2905241205C143998085 @default.
- W2905241205 hasConceptScore W2905241205C202751555 @default.